ABSTRACT
Background: Corneal ulcer is a common cause of blindness in developing countries, as it leads to corneal perforation and blindness if not properly treated.
Objectives: This study aimed to determine the effects of intraocular 5 % and 10 % topical povidone iodine in the treatment of bacterial corneal ulcer in a rabbit model, comparing the effectiveness of vancomycin and cefazolin eye drops.
Materials and Methods: Total of 40 eyes ofrom 20 wild rabbits were randomly assigned to four equal groups, five in each (n = 5), they included; group 1.5 % povidone iodine and vancomycin; group 25 % povidone iodine and cefazolin; group 3.10 % povidone iodine and vancomycin; group 4.10 % povidone iodine and cefazolin (one drop every two hours for seven days and nights). The animals were first anesthetized with ketamine hydrochloride and xylazine chloride. Then, a 27-gauge needle attached to a 1-ml syringe was tunneled through the clear cornea to approximately midstromal depth, stopping at the edge of the 2-mm optical zone. Finally, 0.02 ml of Staphylococcus contaminated media containing about 100 organisms was injected, forming a central intra-stromal infiltrate.
Results: There was no statistically significant difference in the density of infiltration, size of infiltration, hypopyon, or fibrin formation between the four groups. However, epithelial defect, stromal edema, conjunctival injection, and Chemosis were significantly higher in the 5 % and io % povidone iodine groups when compared to the cefazolin and vancomycin groups. Thinning was more common in the cefazolin group. There was one sealed corneal perforation in the cefazolin group at the beginning, and at day 6, one perforation in the cefazolin group and one perforation in the 10 % povidone iodine group also developed.
Conclusions: Cefazolin and vancomycin had a superior clinical effect on the staphylococcal corneal ulcers in this study. 5 % and 10 % povidone iodine was toxic to the corneal epithelium. Thinning and perforation was more common with cefazolin.
Copyright © 2012 Kowsar Corp. All rights reserved.
Keywords:
Corneal Ulcer
Povidone-Iodine
Vancomycin
Cefazolin
1. Background
Corneal ulcer is an infectious condition, and follows the destructive influence of bacteria, viruses and fungi (1). This disease is a common cause of blindness and financial loss in developing countries, and leads to corneal perforation and blindness if not treated properly (2). Staphylococcus species, particularly Staphylococcus aureus and Staphylococcus epidermis are the most common bacterial causes of corneal ulcer in the world (3). The current approved therapies in gram-positive corneal ulcers include drugs such as cefazolin and vancomycin (4). The disadvantages of fortified antibiotics include symptom difficulties such as; burning, redness and eye irritation, being it is relatively expensive and there is a lack or limit of commercial samples.
Povidone iodine is a topical antiseptic that effects bacteria, fungi and viruses by the gradual liberalization of iodine (5). Nowadays, preparations of eye medications with povidone iodine that have a broad-spectrum antibiotic effect at the start of thsurgery are used to prevent post surgical bacterial corneal ulcers (6).
2. Objectives
This study aimed to determine the clinical effects of 5 % and IO % topical povidone iodine in the treatment of bacterial corneal ulcers in a rabbit model, as well as to compare the results with fortified vancomycin and cefazolin eye drops.
3. Materials and Methods
3.1. Animals
Total of 40 eyesfrom 20 wild rabbits (Laboratory Animals Care and Breeding Center of Ahvaz Jundishapur University of Medical Sciences, Ahwaz, Iran), were randomly assigned to 4 equal groups, five in each (n = 5) they included; group 1.5 % povidone iodine (Aida Chemical Co. Iran) eye drops in one eye and fortified vancomycin in the other eye every 2 hours; group 2.5 % povidone iodine eye drops in one eye and fortified cefazolin (Jabber Ibn Hayan Co., Iran) in the other eye every 2 hours; group 3.10 % povidone iodine eye drops in one eye and fortified vancomycin (Jabber Ibn Hayan Co., Iran) in the other eye every 2 hours; group 4.10 % povidone iodine eye drops in one eye and fortified cefazolin in the other eye every 2 hours. Ten variables for all of the rabbits were checked on a daily basis and the results were recorded on the first day - 48 hours after inoculation and before drug therapy - which was considered as the baseline and then the same examinations were applied for seven days, but this time with the instillation of the different drops. All procedures were approved by international guidelines of the Institute Research Ethics and Animal Care and Use Committee of Ahvaz Jundishapur University of Medical Sciences (AJUMS). Every effort was made to minimize the number of animals used and their suffering.
3.2. Surgery and Corneal Ulcer Measurement
The animals were anesthetized with 35mg/kg of ketamine hydrochloride and 5mg/kg xylazine chloride. Each rabbit was given a local anesthetic with tetracaine chloride (Sina Darou, Iran) eye drops. A 27-gauge needle attached to a 1-ml syringe was then tunneled through the clear cornea to approximately midstromal depth, stopping at the edge of the 2-mm optical zone. Then 0.02 ml of Staphylococcus contaminated media containing approximately 100 organisms (ATCC29213) was injected, forming a central intrastromal infiltrate. After 48 hours, the corneas were checked for infection. Rabbits were excluded from the study in cass the absence of the development of a corneal ulcer after five days. Specimens were then collected from the infected corneal ulcers with a swab and samples were sent for culture to ensure that the ulcer had been created by Staphylococcus aureus.
Treatment was started and continued for a week, changes to the dimensions, characteristics and features of the corneal ulcer that were examined by a Topcon SP-78 Specular Microscope (Topcon, Tokyo, Japan). The dimensions of the epithelial defect were measured using/ïuorescent viability staining and then measured with a Moria caliper (Moria S.A., France). 10 variables were checked every day during the therapy. At the conclusion of the study, all variables were given a rating from O to +4, a score for each eye per day was given to a total of ten variables, therefore the scores ranged between zero and 40. Thus, each eye was compared between all four groups during the study.
3.3. Statistical Analysis
Data were tabulated for descriptive and statistical analysis using the analysis of variance (ANOVA) and KruskalWallis test it was deemed appropriate. SPSS 16.0 software was used.
4. Results
All eyes that were evaluated in terms of clinical infections were also confirmed by culture. Two eyes that showed no infection were in the 5 % povidone iodine group; therefore, this group included only 8 eyes.
The defect size (in mm2) at baseline between each of the 4 groups had no significant difference (p value for cefazolin-betadine 5% P= 0.992, for cefazolin-betadine 10 % P= 1, for vancomycin-betadine5 %P= 0.989, for vancomycinbetadinelO %P = 1), however, after starting the second day of drug treatment a significant difference was found, as the group receiving povidone iodine 5 % and 10 % showed significantly higher values than the cefazolin and vancomycin groups. This significant difference continued until the eighth day. (p value for cefazolin-betadine 5 % and for cefazolin-betadine 10 % from the second day to the eighth day was O. ? value for vancomycin betadine 5 % from the second day to the eighth day was 0.001,0,0,0,0,0,0. ? value for vancomycin-betadine 10 % from the second day to eighth day was 0.009, 0.001 ,0,0,0,0,0)
There was no statistically significant difference in the density of infiltration (O to 4+ grading scale), size of infiltration (in mm2), hypopyon (in mm) and fibrin formation (O to 4+ grading scale) between the four groups (Table l).
However, epithelial defect (in mm2), stromal edema (O to 4+ grading scale), conjunctival injection (O to 4+ grading scale), and Chemosis (O to 4+ grading scale) were significantly higher in the 5 % and 10 % povidone iodine groups when compared to the cefazolin and vancomycin groups (Table 2). Thinning was more common in the cefazolin group. There was one sealed corneal perforation in the cefazolin group at the beginning, and on day six; one perforation occurred in the cefazolin group and one perforation in the 10 % povidone iodine group (Table 3). At the end of the study, all ten variables; rat from O to +4; were summed together and a score was given for each eye per day, which produced a number in a range between zero and 40. Thus the eye was compared between all four groups during the study. The course of the drug treatment when the various conditions are carefully compared, revealed the differences between povidone iodine and the other two drugs, and these can be seen in the graph (Figure). Cefazolin and vancomycin exhibited a constant downward slope, but this was not the case of povidone iodine. On the other hand, a similar downward slope was seen on the sixth day for povidone iodine 10 % and on the fourth day in the case of povidone iodine 5 %, which may reveal the need to review the use of Betadine at much lower concentrations.
5. Discussion
Using an anti-microbial agent, that is readily available, inexpensive, easy to use, effective against a wide range of microbes, and which has the least number of complications, has always been the ideal. Despite the large numbers of therapies that have been developed for the treatment of corneal ulcer, many of these useful drugs arenot commercially available yet.
Povidone iodine has traditionally been used to prepare the tissues around the eyes and the eye itself, before applyi ophthalmologic surgery (7). Povidone iodine has been reported to be effective as a topical antibiotic in treating conjunctivitis and keratoconjunctivitis, as well as being effective in the decontamination of donor corneas (8-11). Although this solution has been reported to be an effective method against various microorganisms in vitro (8, U), with only a small spectrum of side effects its clinical effect on infections has not been proven and there is a need forfurther research.
Studies on the effect of povidone iodine in the treatment of ocular infections, including a study that was conducted by Sharma et al. (12) to compare the effect of topical povidone iodine 0.1 %, and gentamicin in the treatment of primary corneal ulcer created by coagulasepositive staphylococcus, have been reported previously. They concluded that povidone iodine is a very effective solution and that it reduces the morbidity period in staphylococcus infection, which was in contrast with the present study. This maybe due to the different concentrations of povidone iodine used in these studies (12).
In agreement with the present study Gregori et al. compared the effect of 5 % povidone iodine with placebo drops (one drop of each.lO minutes before antibiotic treatment) in the treatment of corneal ulcer, and they concluded that the effect povidone iodine has no effect in reducing the number of bacteria on the cornea (13). In agreement with the present study Melki et al. compared the effect of 0.5 % and 10 % povidone iodine with ofloxacin 0.3 % on 21 rabbit eyes for a period of eight hours, and revealed that although 0.5 % povidone iodine has a greater bactericidal effect compare to the untreated cases, but however, its effect is less than ofloxacin (14). Michalova et al. studied the effect of 5 % povidone iodine on Pseudomonas infectious keratitis in rabbits for 24 hours, and claimed that povidone iodine is not effective against Pseudomonas, which was similar to the present study; although it was another infectious organism (15).
Xu-wang Shiun et al. have reported that 2 % povidone iodine is effective in the treatment of dog's infectious conjunctivitis (15). The present study was performed focusing on a larger number of variables compared to similar studies and continued the treatment for 7 days. Epithelial defects clearly increased after only 24 hours in the 5 % and 10 % povidone iodine groups during the 7 days of treatment, and involved almost the entire surface of the cornea in most of the eyes of these two groups, which may indicate the high toxicity of povidone iodine on the epithelium. The lowest toxicity for the epithelium belonged to the cefazolin group.
In the case of the 5 % and 10 % povidone iodine groups, corneal edema was present during the treatment and remained relatively stable, while in the cefazolin and vancomycin groups, corneal edema decreased gradually during the study and was significantly less than in the povidone iodine groups. Considering the results of the present study, it can be said that at least in Staphylococcus keratitis, 5 % and 10 % povidone iodine solutions cannot be used as a good alternative to standard therapies such as cefazolin and vancomycin.
Our study also had other deficiencies, for example despite attempts to inject a similar number of organisms into all of the corneas, different ulcer sizes were observed and that revealed that the number of organisms was probably not quite the same. This may have been due to human error in the injection or reflux of organisms from the injection tunnel within the stroma. In addition, the duration of treatment was short and we should perhaps have assessed longer treatment, although according to the course of change variables it does not seem that we would have obtained a different result with longer treatment. In this study, 5 % and 10 % povidone iodine were toxic to the corneal epithelium. Thinning and perforation were more common than with cefazolin. The ower effect of povidone iodine may have been the result of a lack of deep penetration of this drug into the corneal stroma, but other factors may also be involved.
Acknowledgments
We are thank full to Mr.Latifi for statistical analysis .This paper is issued from thesis of Mr. Najdi (MD)
Financial Disclosure
None declared.
Funding/Support;
This study was supported by agrant from Research deputy of Ahvaz Jundishapur University of Medical sciences. (NO;U-88143)
ARTICLE INFO
Article type:
Original Article
Article history:
Received: 12 Apr 2011
Revised: 30 Dec 2011
Accepted: 09 Jan 2012
* Implication for health policy/practice/research/medical education:
Lower effect of povidone iodine may be the result of the lack of deep penetration of this drug into the corneal stroma, but other factors may be involved.
* Please cite this paper as:
Feghhi M, Amin M, Zamani M, Najdi D. Comparison of Vancomycin and Cefazolin Therapeutic Effect With Povidone Iodine on Corneal Ulcer in Rabbits.Jundishapur J Microbiol. 20i2;5(3):49l-6. DOI: I0.58i2/jjm.4l29
References
1. Garg P, Rao GN. Corneal ulcer: diagnosis and management. Community Eye Health. 1999;l2(30):21-3.
2. Cohen EJ. Cornea and external disease in the new millennium. Arch Ophthalmol. 2000;118(7):979-81.
3. Furlanetto RL, Andreo EG, Finotti IG, Arcieri ES, Ferreira MA, Rocha FJ. Epidemiology and etiologic diagnosis of infectious keratitis in Uberlandia, Brazil. Eur] Oph thalmol. 2010;20(3):498-503.
4. Dhaliwal DK, Mather R. New developments in corneal and external disease-LASIK. Ophthalmol Clin North Am. 2003;l6(l):ll9-25.
5. Darling EK, McDonald H. A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. J Midwifery Womens Health. 20lo;55(4):319-27.
6. Herring IP. Corneal surgery: instrumentation, patient considerations, and surgical principles. Clin Tech Small Anim Pract. 2O03;l8(3):l52-60.
7. Kelkar A Kelkar J, Amuaku W, Kelkar U, Shaikh A How to prevent endophthalmitis in cataract surgeries? Indian J Ophthalmol. 2008;56(5):403-7.
8. Isenberg SJ, Apt L, Campeas D. Ocular applications of povidoneiodine. Dermatology. 2002;204 Suppl 1:92-5.
9. Isenberg SJ, Apt L, Valentón M, Del Signore M, Cubillan L, Labrador MA, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. AmJ Ophthalmol. 2002;l34(5):68l-8.
10. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009;49(10):l541-9.
11. Pels E, Vrensen GF. Microbial decontamination of human donor eyes with povidone-iodine: penetration, toxicity, and effectiveness. Br/Op/it/ia/mo/.1999;83(9):l019-26.
12. Sharma LG, Goyal JK, Sharma U, Chandak GK, Nepalia LK. Evaluation of topical povidone-iodine versus gentamycin in staphylococcus coagulase positive corneal ulcers-an experimental study. Indian] Ophthalmol. 199038(1)30-2.
13. Gregori NZ, Schiffinan JC, Miller DM, Alfonso EC. Clinical trial of povidone-iodine (Betadine) versus placebo in the pretreatment of corneal ulcers. Cornea. 2006;25(5):558-63.
14. Melki SA, Safar A Yaghouti F, Scharper P, Scharper M, Zeligs B, et al. Effect of topical povidone-iodine versus topical ofloxacin on experimental Staphylococcus keratitis. GraefesArch Clin Exp Ophthalmol. 2000;238(5):459-62.
15. Michalova K, Moyes AL, Cameron S, Juni BA Obritsch WF, Dvorak JA, et al. Povidone-iodine (betadine) in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea. 1996;l5(5):533-6.
Mostafa Feghhi1*, Mansour Amin2, Mitra Zamani1, Danial Najdi1
1 Department of Ophthalmology, ophthalmic Research, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Microbiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
* Comsponding author: Mostafa Feghhi, Department of ophthalmology, Imam Khomeini Hospital, ophthalmic Research, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran. Tel: +98-6113738383, Fax: +986113367562, E-mail: [email protected]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright Ahvaz Jundishapur University of Medical Sciences Jul-Sep 2012